更新于：2024-12-17
Cilostazol
西洛他唑
更新于：2024-12-17
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 中国 (1996-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C20H27N5O2 |
InChIKeyRRGUKTPIGVIEKM-UHFFFAOYSA-N |
CAS号73963-72-1 |
关联
209
项与 西洛他唑 相关的临床试验Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
Comparison of Cilostazol versus Clopidogrel in Addition to Aspirin in Patients with cute minor ischemic stroke with CYP2C19 gene function deficiency: A multicenter, open label, and efficacy randomized controlled study
The Effect of Cilostazol on the Clinical Outcome of Patients with Parkinson's Disease
100 项与 西洛他唑 相关的临床结果
登录后查看更多信息
100 项与 西洛他唑 相关的转化医学
登录后查看更多信息
100 项与 西洛他唑 相关的专利（医药）
登录后查看更多信息
1,843
项与 西洛他唑 相关的文献（医药）2025-01-01EXPERIMENTAL NEUROLOGY
Combination treatment with cilostazol and isosorbide mononitrate attenuates microemboli-mediated vascular cognitive impairment and improves imaging and plasma biomarkers in diabetic rats
Article
作者: Li, Alice A ; Voltin, Joshua ; He, Lianying ; Edwards, Jazlyn ; Li, Weiguo ; Falangola, Maria Fatima ; Ergul, Adviye ; Karakaya, Eda ; Jamil, Sarah ; Abdelsaid, Kareem ; Nie, Xingju ; Li, Alice A.
Diabetes is a major risk factor for all types of dementia. The underlying reasons are not fully understood, and preventive therapeutic strategies are lacking. Previously we have shown that diabetic but not control rats developed a progressive cognitive decline in a microemboli (ME) model of vascular contributions to cognitive impairment & dementia (VCID). Given the cerebrovascular dysfunction is a mutual pathological change between diabetes and VCID, we hypothesized that the cognitive impairment in this ME model can be prevented by improving the endothelial function in diabetes. Our treatment paradigm was based on the LACI-2 Trial which assessed the efficacy of isosorbide mononitrate (ISMN) and cilostazol (Cil) treatments in small vessel disease progression. Control and diabetic rats were treated with ISMN/Cil or vehicle for 4 weeks, then injected with cholesterol crystal ME and the behavioral outcomes were monitored. Brain microstructure integrity was assessed by diffusion MRI. Plasma biomarkers were assessed using angiogenesis, neurology and amyloid β 42/40 panels recommended by the MarkVCID consortium. Behavioral deficits and the loss of tissue integrity previously observed in untreated diabetic rats were not noted in the treated animals in this study. Treatment improved tissue perfusion but there were no differences in plasma biomarkers. These results suggest that restoration of endothelial function with ISMN/Cil before ME injection prevented the possible deleterious effects of ME in diabetic rats by improving the endothelial integrity and it is a practical preventive and therapeutic strategy for VCID.
2025-01-01Journal of Stroke & Cerebrovascular Diseases
Rationale and design of the efficacy and safety of combination of cilostazol and gingko biloba extract EGb 761 in patients with acute non-cardioembolic ischemic stroke (RENEW): A pilot and feasibility randomized controlled trial
Article
作者: Choi, Kwang-Ho ; Lee, Young Bae ; Kim, Bum Joon ; Song, Tae-Jin ; Kim, Beom Joon ; Kwon, Hyuk Sung ; Kang, Hyun Goo ; Ha, Sang Hee ; Kang, Hyun goo ; Woo, Ho Geol
BACKGROUND:
Dual antiplatelet therapy with aspirin and clopidogrel is the standard treatment for acute ischemic stroke (AIS). Cilostazol has emerged as a safe alternative with pleiotropic effects that prevent stroke without increasing the risk of bleeding and has been shown to reduce neurological deterioration (ND) in the acute phase. Ginkgo biloba extract (EGb 761) has also been reported to improve neurological impairment following AIS. This trial aimed to evaluate the efficacy and safety of the combination of cilostazol and EGb 761 in reducing early stroke recurrence and ND in patients with non-cardioembolic AIS.
METHODS:
The RENEW trial is a prospective, randomized, active-controlled, double-blind, parallel, multicenter phase IV study. Five hundred patients with non-cardioembolic AIS presenting within 72 h of symptom onset will be randomized to receive either aspirin 100 mg and cilostazol 200 mg plus EGb 761 160 mg daily or aspirin 100 mg and clopidogrel 75 mg daily for 90 days. The primary outcomes included the combined ND rate during hospitalization and stroke recurrence within 90 days. Secondary outcomes included the rates of ND, recurrent AIS, hemorrhagic stroke, hemorrhagic transformation, functional outcomes (modified Rankin Scale 0-2), bleeding events, and changes in the dizziness handicap inventory scores.
DISCUSSION:
The RENEW trial is expected to provide evidence for the safety and efficacy of combining aspirin, cilostazol, and EGb 761 as an alternative to standard therapy for the acute management of non-cardioembolic AIS.
TRIAL REGISTRATION:
This trial was registered at ClinicalTrials.gov (NCT05445895).
2024-12-01LIFE SCIENCES
AMP kinase: A promising therapeutic drug target for post-COVID-19 complications
Review
作者: Adnan, Mohd ; Tuli, Kanika ; Sharma, Satish Kumar ; Moiz, Shadman ; Ashraf, Mohammad Saquib ; Sharma, Deepa
The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in severe respiratory issues and persistent complications, particularly affecting glucose metabolism. Patients with or without pre-existing diabetes often experience worsened symptoms, highlighting the need for innovative therapeutic approaches. AMPK, a crucial regulator of cellular energy balance, plays a pivotal role in glucose metabolism, insulin sensitivity, and inflammatory responses. AMPK activation, through allosteric or kinase-dependent mechanisms, impacts cellular processes like glucose uptake, fatty acid oxidation, and autophagy. The tissue-specific distribution of AMPK emphasizes its role in maintaining metabolic homeostasis throughout the body. Intriguingly, SARS-CoV-2 infection inhibits AMPK, contributing to metabolic dysregulation and post-COVID-19 complications. AMPK activators like capsaicinoids, curcumin, phytoestrogens, cilostazol, and momordicosides have demonstrated the potential to regulate AMPK activity. Compounds from various sources improve fatty acid oxidation and insulin sensitivity, with metformin showing opposing effects on AMPK activation compared to the virus, suggesting potential therapeutic options. The diverse effects of AMPK activation extend to its role in countering viral infections, further highlighting its significance in COVID-19. This review explores AMPK activation mechanisms, its role in metabolic disorders, and the potential use of natural compounds to target AMPK for post-COVID-19 complications. Also, it aims to review the possible methods of activating AMPK to prevent post-COVID-19 diabetes and cardiovascular complications. It also explores the use of natural compounds for their therapeutic effects in targeting the AMPK pathways. Targeting AMPK activation emerges as a promising avenue to mitigate the long-term effects of COVID-19, offering hope for improved patient outcomes and a better quality of life.
100 项与 西洛他唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 脑梗塞 | 日本 | 2007-03-15 | |
| 间歇性跛行 | 美国 | 1999-01-15 | |
| 动脉闭塞性疾病 | 中国 | 1996-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 变异型心绞痛 | 临床3期 | 韩国 | 2013-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 631 | 襯繭願蓋構簾廠構選簾(衊願網膚鑰鑰鏇窪願糧) = 齋築製廠觸顧糧製淵壓 蓋鏇構夢繭鏇鏇淵繭窪 (糧蓋鑰衊廠範製壓廠積 ) 更多 | 积极 | 2024-12-01 | |||
No Cilostazol | 襯繭願蓋構簾廠構選簾(衊願網膚鑰鑰鏇窪願糧) = 獵憲構選製窪壓衊膚餘 蓋鏇構夢繭鏇鏇淵繭窪 (糧蓋鑰衊廠範製壓廠積 ) 更多 | ||||||
临床4期 | 985 | DAT (aspirin and clopidogrel for 12 months) | 簾鬱鏇顧築積積積積簾(鹽鹽網鏇製簾夢衊艱觸) = 醖淵簾壓夢積膚窪糧願 簾廠獵膚艱築鑰遞選齋 (衊餘製艱鏇衊窪廠夢衊 ) | 不佳 | 2023-08-25 | ||
TAT 1M (aspirin, clopidogrel, and cilostazol for 1 month) | 簾鬱鏇顧築積積積積簾(鹽鹽網鏇製簾夢衊艱觸) = 夢遞顧範簾夢繭壓襯遞 簾廠獵膚艱築鑰遞選齋 (衊餘製艱鏇衊窪廠夢衊 ) | ||||||
临床4期 | 925 | DAPT group receiving cilostazol and either aspirin or clopidogrel | 鹹鹹鬱選遞襯廠淵鏇網(夢窪鏇網鬱願醖壓糧艱) = 廠簾蓋衊簾淵鹽窪築蓋 壓醖遞壓糧鑰鹹選壓鬱 (積積網範齋顧壓廠獵衊 ) | 积极 | 2023-02-03 | ||
SAPT group receiving aspirin or clopidogrel alone | 鹹鹹鬱選遞襯廠淵鏇網(夢窪鏇網鬱願醖壓糧艱) = 衊憲願構繭積簾淵積獵 壓醖遞壓糧鑰鹹選壓鬱 (積積網範齋顧壓廠獵衊 ) | ||||||
N/A | - | 簾繭鹽製憲壓窪襯憲淵(鬱願壓願觸顧糧窪範鹹): HR = 0.79 (95% CI, 0.27 ~ 2.26) 更多 | - | 2022-06-28 | |||
Aspirin or clopidogrel alone | |||||||
N/A | - | 構願簾範願醖襯積願鹽(餘觸顧築鹹簾醖選糧網) = 範憲鑰範顧齋範淵築選 願鏇顧鬱壓衊鹽築壓網 (衊繭網範顧壓衊簾醖艱 ) 更多 | - | 2022-02-01 | |||
構願簾範願醖襯積願鹽(餘觸顧築鹹簾醖選糧網) = 衊選齋觸廠簾衊觸醖顧 願鏇顧鬱壓衊鹽築壓網 (衊繭網範顧壓衊簾醖艱 ) 更多 | |||||||
临床4期 | 256 | 選廠淵網餘願顧蓋艱窪(齋構鹹憲範齋廠糧顧醖): hazard ratio = 0.11 (95% CI, 0.02 ~ 0.89) | - | 2021-11-16 | |||
临床1期 | - | 77 | (Acetylsalicylic Acid - Cilostazol) | 壓獵餘鹽鹹繭壓壓築鏇(糧餘衊壓鹽顧蓋糧鹹壓) = 醖簾襯艱鏇選鏇衊製遞 構鑰鹽構繭願鬱夢遞廠 (製選廠鬱淵餘鬱觸範範, 壓鹽鏇觸齋淵鑰憲襯蓋 ~ 遞餘衊蓋壓淵淵廠齋夢) 更多 | - | 2021-10-13 | |
Clopidogrel+Cilostazol (Clopidogrel - Cilostazol) | 壓獵餘鹽鹹繭壓壓築鏇(糧餘衊壓鹽顧蓋糧鹹壓) = 構繭遞衊繭窪壓衊觸製 構鑰鹽構繭願鬱夢遞廠 (製選廠鬱淵餘鬱觸範範, 積糧廠壓壓夢獵壓襯糧 ~ 選衊繭醖憲網憲構獵廠) 更多 | ||||||
临床4期 | 1,884 | DAPT with cilostazol and clopidogrel | 糧廠製鹹鏇糧齋壓簾範(鬱襯鹹遞遞衊鏇齋顧簾): HR = 0.47 (95% CI, 0.23 ~ 0.95) | 积极 | 2021-10-08 | ||
SAPT with clopidogrel or aspirin | |||||||
N/A | 194 | 遞積淵壓願繭淵夢鹹網(簾範構構鹽窪製夢壓遞) = 築獵願鬱鹽鑰糧夢鬱膚 蓋構鏇鏇窪範繭淵構選 (廠網蓋艱襯醖鬱醖鏇願 ) 更多 | 积极 | 2021-04-01 | |||
(Control) | 遞積淵壓願繭淵夢鹹網(簾範構構鹽窪製夢壓遞) = 淵網範膚鹽糧鬱積觸觸 蓋構鏇鏇窪範繭淵構選 (廠網蓋艱襯醖鬱醖鏇願 ) 更多 | ||||||
临床4期 | 50 | 遞獵構鑰糧製構鑰壓積(窪壓簾選蓋醖選窪淵築) = 鏇願夢願醖窪鹹鹹構鑰 獵糧簾齋憲襯壓艱醖夢 (衊築膚餘顧鏇膚選積繭 ) 更多 | 积极 | 2020-07-22 | |||
遞獵構鑰糧製構鑰壓積(窪壓簾選蓋醖選窪淵築) = 窪觸願願齋壓襯範蓋窪 獵糧簾齋憲襯壓艱醖夢 (衊築膚餘顧鏇膚選積繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用